Filing Overview
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022, not a filing under the name Spyre Therapeutics, Inc. The company is a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare metabolic diseases. Its lead programs were pegzilarginase for Arginase 1 Deficiency, AGLE-177 for Homocystinuria, and AGLE-325 for Cystinuria.
The company operated as a single business segment and had 49.4 million common shares outstanding as of March 31, 2022; 50.4 million shares were outstanding as of April 28, 2022.
Financial Highlights
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $1.4 million | $0 | Up $1.4 million |
| Research and development expense | $17.0 million | $11.9 million | Up 43% |
| General and administrative expense | $8.8 million | $6.4 million | Up 39% |
| Total operating expenses | $25.8 million | $18.2 million | Up 42% |
| Loss from operations | $24.4 million | $18.2 million | Loss increased $6.2 million |
| Net loss | $24.4 million | $18.2 million | Loss increased 34% |
| Basic and diluted net loss per share | $0.37 | $0.28 | Loss per share increased |
| Net cash used in operating activities | $26.3 million | $19.5 million | Use increased $6.7 million |
Q1 2022 revenue consisted of development-fee revenue under the Immedica license and supply agreement. The company had no commercial product revenue.
Balance Sheet, Liquidity and Capital Resources
- Cash and cash equivalents were $14.6 million, compared with $15.1 million at December 31, 2021.
- Marketable securities were $52.1 million, down from $78.0 million at December 31, 2021.
- Cash, cash equivalents, marketable securities and restricted cash totaled $68.6 million at March 31, 2022.
- Working capital was $56.3 million, and accumulated deficit was $366.2 million.
- The company reported no debt or credit facility and no additional committed capital.
- Net cash used in operating activities was partly offset by $25.8 million of investing cash inflow, primarily maturities of marketable securities.
- The company had $6.7 million of future minimum lease commitments through April 2028.
Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations into the first quarter of 2023. However, management concluded that substantial doubt existed about the company’s ability to continue as a going concern within twelve months after issuance of the financial statements because of recurring losses, expected continued operating losses and the need for additional financing.
Material Changes from the Prior Comparable Period
- Revenue increased from zero to $1.4 million due to development services performed for Immedica.
- Research and development expense increased $5.1 million, driven by approximately $2.0 million of BLA submission activities, $1.9 million of higher clinical trial and patient-related costs, and $1.2 million of higher personnel costs.
- General and administrative expense increased $2.5 million, primarily from ramping commercial capabilities and infrastructure and higher compensation costs.
- Operating cash burn increased from $19.5 million to $26.3 million.
- Marketable securities declined $25.9 million as the company used investment maturities to support operations.
- Stock-based compensation increased to $2.1 million from $1.8 million.
Business Developments and Outlook
- The company announced positive topline and additional PEACE Phase 3 data for pegzilarginase, including a statistically significant reduction in plasma arginine and achievement of normal arginine levels in 90.5% of treated patients versus none in the placebo arm.
- Despite the reported clinical data, the FDA stated after a February 2022 Type B meeting that the data appeared promising and hypothesis-generating but did not provide substantial evidence of effectiveness. The FDA reiterated that an additional randomized, placebo-controlled trial longer than 24 weeks may be needed.
- The company submitted a BLA for pegzilarginase in April 2022, while acknowledging that the FDA might not file or approve the application and could require additional studies.
- AGLE-177 was in a Phase 1/2 trial for Homocystinuria. The company expected to report initial clinical data in the second half of 2022.
- The company planned to advance AGLE-325 through IND-enabling studies in 2022.
- The Immedica agreement provides potential regulatory and commercial milestone payments of up to approximately $125.0 million and royalties in the mid-20% range on net sales in specified territories. These amounts were not included in current revenue because the relevant milestones were constrained or subject to sales-based recognition rules.
- Management expected expenses and losses to increase as clinical development, commercialization preparation, pipeline development, intellectual-property activities and public-company costs continued.
Key Risks, Contingencies and Unusual Items
- Going concern: Additional capital is required. Management expected to pursue equity offerings, private placements, debt financing, collaborations or other strategic transactions, but no financing was committed.
- Regulatory risk: The FDA’s concerns regarding the PEACE Phase 3 trial could delay or prevent approval of pegzilarginase and require additional clinical testing.
- Clinical and safety risk: Product candidates remain investigational, and clinical outcomes, enrollment, safety, efficacy and long-term tolerability remain uncertain.
- COVID-19: The pandemic had caused missed dosing, enrollment delays and potential disruptions involving clinical sites, suppliers, manufacturing, distribution and regulatory review.
- Manufacturing dependence: The company relied on third-party contract research and manufacturing organizations and had no redundant supply arrangement for bulk drug substance.
- Dilution risk: The company had 16.6 million pre-funded warrants outstanding at March 31, 2022, generally exercisable for $0.0001 per share and potentially exercisable for little or no additional cash.
- Investments: Marketable securities had $158,000 of unrealized losses at March 31, 2022. Management attributed the losses to market conditions rather than credit deterioration and recorded no credit-loss allowance.
- Legal proceedings: Management reported no pending claims or actions expected to have a material adverse effect on results, financial condition or cash flows.
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level, with no material changes in internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify that the supplied filing is for Aeglea BioTherapeutics, Inc. rather than Spyre Therapeutics, Inc., including the issuer name, ticker AGLE and historical corporate identity.
- Confirm the FDA’s position on the PEACE Phase 3 data, the status of the submitted BLA and whether additional trials or follow-up were required.
- Reconcile the $68.6 million liquidity figure with cash, marketable securities and restricted cash, and assess the projected funding runway beyond the first quarter of 2023.
- Review any subsequent equity, debt, collaboration or strategic transactions undertaken to address the going-concern uncertainty.
- Evaluate potential dilution from the 16.6 million outstanding pre-funded warrants, equity compensation and future financings.
- Track AGLE-177 enrollment, clinical data and any effects from COVID-19-related delays.
- Review the terms, recognition and collectability of remaining Immedica development fees, milestones and royalties.